Renal tubulointerstitial injury induced by pembrolizumab in patients with lung adenocarcinoma

VernacularTitle:帕博利珠单抗致肺腺癌患者肾小管间质损伤
Author: Hongyu ZHANG ¹ ; Fei TENG ; Wei YE ; Yubing WEN ; Ke ZHENG
Author Information

1. 雅安市人民医院肾内科，雅安　625000
Publication Type:Journal Article
Keywords: Immune checkpoint inhibitors; Lung neoplasms; Kidney injury; Pabolizumab
From: Adverse Drug Reactions Journal 2023;25(8):504-505
CountryChina
Language:Chinese
Abstract: A 67-year-old female patient with lymph node metastasis from lung adenocarcinoma received the treatment of chemotherapy, immunotherapy, and targeted therapy (cisplatin, pemetrexed, pembrolizumab, and lenvatinib) at the same time. After the end of the third cycle of treatment, the patient developed elevated blood pressure (160/100 mmHg), blood creatinine increase (from 90 μmol/L to 160 μmol/L), anemia (hemoglobin 90 g/L), and metabolic acidosis (total carbon dioxide 18 mmol/L). Renal histopathological examination showed tubulointerstitial damage. Excluding kidney injury caused by other drugs, it was considered to be the immune adverse reaction caused by pembrolizumab. The drug was discontinued and hormone, antihypertensive, and symptomatic treatments were given. After 5 months, the patient′s blood pressure was 110-120/70-80 mmHg, serum creatinine decreased to 130 μmol/L, hemoglobin was 117 g/L, and total carbon dioxide was 26 mmol/L.